Chebulic acid

Other Names

(2S)-2-[(3S)-3,4-Dihydro-3α-carboxy-5,6,7-trihydroxy-1-oxo-1H-2-benzopyran-4β-yl]butanedioic acid(2S)-2-[(3S,4S)-3-carboxy-5,6,7-trihydroxy-1-oxo-3,4-dihydro-1H-2-benzopyran-4-yl]butanedioic acid(2S)-2-[(3S,4S)-3-Carboxy-5,6,7-trihydroxy-1-oxo-3,4-dihydro-1H-isochromen-4-yl]succinic acid(2S)-2-[(3S,4S)-3-carboxy-5,6,7-trihydroxy-1-oxo-3,4-dihydroisochromen-4-yl]butanedioic acid(2S)-[(3S,4S)-3-carboxy-3,4-dihydro-5,6,7-trihydroxy-1-oxo-1H-2-benzopyran-4-yl]-butanedioic acidButanedioic acid, 2-[(3S,4S)-3-carboxy-3,4-dihydro-5,6,7-trihydroxy-1-oxo-1H-2-benzopyran-4-yl]-, (2S)-

Synopsis

Chebulic Acid: A Comprehensive Encyclopedic Reference

1. Identity: Chemical and Botanical Profile

1.1 Names and Classification

Chebulic acid is a phenolic compound isolated from the ripe fruits of Terminalia chebula. Its Chemical Abstracts Service (CAS) registry number is 23725-05-5, and its molecular formula is C₁₄H₁₂O₁₁, as recorded in the PubChem Compound Database (CID 71308174). This compound possesses an isomer, neochebulic acid, and is also a component of transformed ellagitannins such as chebulagic acid and chebulinic acid.

Chebulic acid belongs to the broader phenolic acid and hydrolyzable tannin family. It is important to distinguish it clearly from two related but chemically distinct compounds that share a similar name and the same botanical source:

Chebulagic acid — a benzopyranone-type ellagitannin.
Chebulinic acid — a natural product in the family of ellagitannins, or hydrolyzable tannins, which consist of polyphenols surrounding a glucose center, found in plants such as Euphoria longana and Terminalia chebula (both tropical Asian fruit trees) and T. macroptera (a central African flowering tree).

While all three are co-isolated from Terminalia chebula and are pharmacologically related, chebulic acid (CAS 23725-05-5) is structurally the smallest of the three and represents a phenolic acid subunit rather than a complete ellagitannin. The present article focuses primarily on chebulic acid (CAS 23725-05-5), with reference to closely related compounds where the science is explicitly attributed to them by primary sources.

1.2 Natural Sources

Chebulic acid is isolated from the ripe fruits of Terminalia chebula. A hepatoprotective compound was isolated from the ethanolic extract of the fruits of Terminalia chebula Retz. by consecutive solvent partitioning, followed by silica gel and Sephadex LH-20 column chromatographies. The purified compound was identified as a mixture of chebulic acid and its minor isomer, neochebulic acid, with a ratio of 2:1 by spectroscopic analysis including 1D and 2D NMR and MS spectroscopy.

Terminalia chebula (family Combretaceae) is the primary documented source for chebulic acid. The parent plant is a medium-to-large-sized deciduous tree. Native to South and Southeast Asia, it is highly regarded in both Tibetan and Ayurvedic medicine. T. chebula is a medium-to-large-sized tree belonging to the Combretaceae family. Known as Chebulae Fructus (CF), its dried fruit is extensively used, especially in China, Nepal, India, Myanmar, Sri Lanka, Thailand, and Bangladesh, among others.

It has been found that CF contains at least 149 chemical compounds, which comprise 60 tannins, 28 phenolic acids, 15 lignans, 20 triterpenoids, 6 flavonoids, 9 volatiles, and 11 other compounds, such as carboxylic acids and steroids. Chebulic acid is one of the phenolic acid constituents within this complex phytochemical matrix.

1.3 Common Forms and Preparations

In research and commercial settings, chebulic acid is obtained as a purified isolate from T. chebula fruit ethanolic or aqueous extracts, typically with purity ranging from 95–99% as assessed by HPLC-DAD or HPLC-ELSD methods. As a dietary supplement ingredient, it reaches consumers primarily through preparations of the whole fruit or standardized extracts of T. chebula, often as part of multi-herb formulations such as Triphala. CF is celebrated as the king of Tibetan medicines and is consistently named first in the Ayurvedic Materia Medica; it has gained popularity as a nutraceutical food and dietary supplement. Standardized extracts are commonly available as powders and capsules. Because chebulic acid is present as part of the tannin fraction, whole-fruit preparations will also deliver co-occurring compounds such as chebulagic acid, chebulinic acid, gallic acid, and ellagic acid.

2. Traditional and Historical Use

2.1 Ayurvedic Medicine (India)

Terminalia chebula Retz., known for its dried fruit, namely Chebulae Fructus, is a medicinal plant with a long-standing global reputation, which was initially recognized for its therapeutic properties during the Jin Dynasty. In India's Ayurvedic system, the dried ripe fruit — known as Haritaki — holds a position of exceptional importance. It has common names such as dark myrobalan, ink tree, or chebulic myrobalan (English), haritaki (Sanskrit and Bengali), Harad (Hindi), Harada (Marathi and Gujarati), Karkchettu (Telugu), and Kadukkaya (Tamil).

Terminalia chebula is a gentle purgative, astringent (unripe fruits are more purgative, ripe ones are more astringent), stomachic, antibilious, and ulcerative. It is used in prescriptions for treating flatulence, constipation, diarrhea, dysentery, cyst, digestive disorders, vomiting, enlarged liver and spleen, cough and bronchial asthma, and for metabolic harmony. The Ayurvedic Pharmacopoeia of India, along with other therapeutic applications, indicated the use of powder of mature fruits in intermittent fevers, chronic fevers, anaemia and polyuria.

The fruits of T. chebula are used in combination with Emblica officinalis and T. bellerica (under the name Triphala) in the treatment of liver and kidney dysfunctions. The main purgative ingredient of Triphala is T. chebula.

In traditional Chinese medicine (TCM), the fruit is designated He Zi (河子) or Chebulae Fructus. In China, the fruit is used as a carminative, deobstruent, astringent, and expectorant agent and also as a remedy for salivating and heartburn.

2.2 Tibetan Medicine

In traditional Tibetan medicine, T. chebula refers to the dried fruit of a plant in the Combretaceae family. It is primarily grown in Malaysia, India, and Myanmar and is also found in various regions of China, including Yunnan, Tibet, Guangdong, and Guangxi. CF is celebrated as the king of Tibetan medicines.

2.3 The Triphala Formulation

Triphala is a critical herbal blend in Ayurveda, the traditional Indian medical system, consisting of three medicinal fruits: Terminalia chebula Retz., Phyllanthus emblica Linn., and Terminalia belerica Retz. Chemical changes occurring during the fermentation process of Abhayarishta (an Ayurvedic formulation) traditionally prepared from the fermentation of Embelia ribes (fruits), Terminalia chebula (pericarp), Vitis vinifera (fruits), and Madhuca indica (flowers) decoction have been characterized by HPLC-DAD method.

2.4 TCM and Historical Recognition

Hydrolyzable tannins from the fruits and leaves of plants that contain chebulinic acid are used in traditional Chinese medicine; consequently, the acid has been widely studied for its pharmacological properties. The phytochemical history of chebulinic acid extends at least to 1911: chebulinic acid has been known since 1911, when German scientist W. Richter described it under the name "eutannin." In 2006, Hongxi Xu and co-workers at the Hong Kong Jockey Club Institute of Chinese Medicine reported the preparative isolation of it and the similar molecule chebulagic acid.

3. Key Constituents and Phytochemical Context

Chebulic acid is one of many bioactive components found in T. chebula fruit. Understanding the compound requires situating it within the broader phytochemical profile of the plant.

Terminalia chebula contains chebulagic acid, chebulic acid, tannic acid, gallic acid (~1.2%), ethyl gallate, ellagic acid, chebulinic acid, chebulanin, corilagin, terflavin A, punicalagin, terchebulin, casuarinin, 2,4-chebulic-β-D-glucose and glucose esterified with gallic acid to various degrees (e.g., 1,6-O-galloyl-β-D-glucopyranose), and hydroxy anthraquinone glycosides.

Contemporary pharmacological research has demonstrated that CF primarily exhibits antioxidant properties due to its rich production of phenolcarboxylic and tannic antioxidants, such as chebulagic acid, chebulinic acid, gallic acid, and ellagic acid. These compounds are highly effective in preventing oxidative stress and inhibiting oxygen- or peroxide-induced reactions.

Hydrolyzable tannoids have been reported as key bioactive components of T. chebula. Chebulagic acid and chebulinic acid are the two major bioactive hydrolyzable tannoids of T. chebula.

4. Established Mechanisms of Action

4.1 Antioxidant Activity and Nrf2 Pathway Activation

Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs.

The first report on the protection of rat hepatocytes against oxidative toxicity by chebulic acid obtained from T. chebula Retz. demonstrated that this compound exhibited in vitro free radical-scavenging activity and ferric-reducing antioxidant activity. Using isolated rat hepatocyte experiments, chebulic acid significantly reduced the tert-butyl hydroperoxide (t-BHP)-induced cell cytotoxicity, intracellular reactive oxygen species level, and the ratio of GSSG to total GSH (4.42%) compared to t-BHP alone (8.33%).

A major pathway through which chebulic acid exerts its cytoprotective effects is activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor. The purpose of relevant research was to investigate the hepatoprotective mechanism of chebulic acid against oxidative stress produced by tert-butyl hydroperoxide (t-BHP) in liver cells. The treatment with chebulic acid attenuated cell death in t-BHP-induced HepG2 liver cells and increased intracellular glutathione content, upregulated the activity of heme oxygenase-1, and also increased the translocation of Nrf2 into the nucleus and Nrf2 target gene expression in a dose-dependent manner. The exposure of chebulic acid activated the phosphorylation of mitogen-activated protein kinases. The overall result is that chebulic acid has a cytoprotective effect on t-BHP-induced hepatotoxicity in HepG2 cells through Nrf2-mediated antioxidant enzymes.

Chebulic acid induces Nrf2 nuclear translocation and glutathione synthesis and inhibits glycer-AGE-induced collagen accumulation, a marker of fibrosis, in LX-2 hepatic stellate cells.

4.2 Anti-Glycation (AGE Inhibition and Breaking)

Chebulic acid (CA), isolated from Terminalia chebula, has been reported to break the cross-links of proteins induced by AGEs and to inhibit the formation of AGEs. In direct comparisons with established reference compounds, chebulic acid demonstrates potent antiglycation activity: aminoguanidine (AG) reduced 50% of glycated bovine serum albumin (BSA) with glycolaldehyde-induced cross-links of collagen at a concentration of 67.8 ± 2.5 mM; the level of CA required for exerting a similar antiglycating activity was 38.8 ± 0.5 µM. Also, the breaking activity on collagen cross-links was potent with CA (IC50 = 1.46 ± 0.05 mM), exhibiting 50-fold stronger breaking activity than with ALT-711, a well-known cross-link breaker (IC50 = 72.2 ± 2.4 mM).

CA could be a breaker as well as an inhibitor of AGE cross-linking, the activity of which may be explained in large part by its chelating and antioxidant activities, suggesting that CA may constitute a promising antiglycating candidate in intervening AGE-mediated diabetic complications.

4.3 Anti-Inflammatory Mechanisms

Chebulagic acid, a natural antioxidant, has shown potent anti-inflammatory effects in LPS-stimulated RAW 264.7 mouse macrophage cells. These effects were exerted via inhibition of NO and PGE2 production and down-regulation of iNOS, COX-2, 5-LOX, TNF-α and IL-6. The compound inhibited NF-κB activation by LPS, and this was associated with the abrogation of IκB-α phosphorylation and subsequent decreases in nuclear p50 and p65 protein levels. (Note: this specific set of data pertains to chebulagic acid from T. chebula, a closely related ellagitannin, and is included here as representative of the mechanistic cluster documented for the tannin fraction of the plant.)

Compounds such as corilagin, chebulanin, chebulagic acid, and chebulinic acid are cited for their efficacious impact in mitigating arthritis symptoms. Their anti-inflammatory activity is mainly achieved through the NF-κB and MAPK signaling pathways.

4.4 ERK/Nrf2 Pathway in Vascular Protection

Human endothelial venous umbilical cells (HUVEC) treated with 10 µM CA prior to glyceraldehyde-induced AGEs treatment showed a substantial improvement in nuclear Nrf2 level through activation of extracellular signal-regulated kinase (ERK), and oral administration of 10 mg of CA/kg b.w. for 2 weeks and 5 days at the same time injected with AGEs showed improved Nrf2 expression.

5. Scientific Evidence by Area of Use

5.1 Diabetes and Metabolic Disease

Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications

A published study investigated the protective mechanism of chebulic acid, a phenolcarboxylic acid compound isolated from the ripe fruits of Terminalia chebula, against advanced glycation endproducts (AGEs)-induced endothelial cell dysfunction. To investigate the protective mechanism against vascular endothelial dysfunction, human umbilical vein endothelial cells (HUVEC) were treated with chebulic acid in the presence/absence of glyceraldehyde-related AGEs. HUVEC incubated with 100 µg/ml of glycer-AGEs had significantly enhanced reactive oxygen species formation, whereas the treatment of chebulic acid dose-dependently reduced glycer-AGE-induced formation to 108.2 ± 1.9% for 25 µM versus 137.8 ± 1.1% for glycer-AGEs treated alone. The transendothelial electrical resistance (TER) value of the glycer-AGEs group was dramatically decreased to 76.9 ± 2.2% compared to the control, whereas chebulic acid treatment prevented glycer-AGE-induced TER change with a value of 91.3 ± 5.3%.

The incubation of confluent HUVEC with glycer-AGEs for 24 h remarkably increased the adhesion of human monocytic THP-1 cells compared to non-stimulated HUVEC; these increases in HUVEC adhesiveness were dose-dependently reduced by chebulic acid. The present study shows the effects of chebulic acid against the progression of AGE-induced endothelial cell dysfunction, suggesting that this compound may constitute a promising intervention agent against diabetic vascular complications.

Evidence strength: This is in vitro (cell-based) evidence only. No clinical (human) trials have been conducted specifically on isolated chebulic acid for diabetic vascular outcomes.

Pancreatic β-Cell Protection and Methylglyoxal (MG) Toxicity

To investigate the anti-diabetic properties of chebulic acid (CA) associated with the prevention of methylglyoxal (MG)-induced mitochondrial dysfunction in INS-1 pancreatic β-cells, INS-1 cells were pre-treated with CA (0.5, 1.0, and 2.0 µM) for 48 h and then treated with 2 mM MG for 8 h. CA (0.5–2.0 µM) significantly prevented the formation of ROS in INS-1 β-cells. However, molar-level pre-treatment with 0.5 mM NAC, a compound well-known as a free radical scavenger, did not suppress MG-induced ROS production significantly; NAC treatment was used as a positive control at a molar concentration 250–1000 fold that of the CA level. These findings suggest that CA acts as a potent antioxidant while increasing Glo-1 and protecting the pancreas from MG toxicity.

Evidence strength: Preliminary in vitro evidence in cell lines only. Not tested in human subjects.

Ischemia-Reperfusion in Diabetic Animals

Chebulic acid is a phenol with diverse biological activities. In vivo, chebulic acid (25 and 50 mg/kg) increases serum insulin levels and reduces blood urea nitrogen levels, proteinuria, albuminuria, and serum glucose levels in a diabetic rat model of ischemia-reperfusion-induced nephropathy.

Evidence strength: Animal (rodent) model data only; no human clinical evidence is available for this specific application.

5.2 Liver (Hepatoprotective) Effects

Hepatoprotective activity constitutes one of the most extensively explored areas for chebulic acid across multiple in vitro and in vivo systems.

In animal experiments, CA significantly protected mice from CCl4-induced liver injury, as demonstrated by reduced ALT, AST and MDA levels, enhanced SOD activity, improved liver histopathological changes, and the activation of the Nrf2/HO-1 signaling pathway. Chebulic acid could also attenuate advanced glycation end products-mediated vascular dysfunction by inhibiting the production of ROS via the ERK/Nrf2 pathway.

In hepatocyte models, treatment with chebulic acid attenuated cell death in t-BHP-induced HepG2 liver cells and increased intracellular glutathione content, upregulated the activity of heme oxygenase-1, and increased the translocation of Nrf2 into the nucleus and Nrf2 target gene expression in a dose-dependent manner.

In a study, pretreatment with chebulinic acid was found to mitigate t-BHP-induced damage in L-02 hepatocytes.

Studies have demonstrated that higher doses of CF (600 mg/kg) exhibit significant therapeutic potential, particularly showing enhanced anti-diabetic and antilipidemic effects. Additionally, these doses offer pronounced hepatoprotective and renoprotective benefits compared to lower doses.

Evidence strength: Predominantly in vitro (HepG2, L-02 hepatocyte cell line) and in vivo animal (mouse, rat) model studies. No specific human clinical trials on chebulic acid as an isolated compound for hepatoprotection have been identified in available peer-reviewed literature.

5.3 Anti-Fibrotic Effects (Hepatic Fibrosis)

Chebulic acid prevents hepatic fibrosis induced by advanced glycation end-products in LX-2 human hepatic stellate cells by modulating Nrf2 translocation via the ERK pathway (published in Toxicology in Vitro). In this study, chebulic acid inhibited collagen accumulation in LX-2 stellate cells — a well-established in vitro model of hepatic fibrosis — through a mechanism involving Nrf2-mediated upregulation of antioxidant enzymes and suppression of AGE-induced pro-fibrotic signaling.

Previous studies have demonstrated CA's anti-oxidant ability and its effectiveness in preventing hepatic fibrosis, lung damage owing to urban particulate matter, and vascular dysfunction.

Evidence strength: In vitro evidence in human hepatic stellate cell lines. No animal or human clinical evidence specific to this endpoint.

5.4 Respiratory / Lung Protection

Chebulic acid (CA) isolated from T. chebula, which has been reported for treating asthma, is a potent antioxidant resource. Exposure to ambient urban particulate matter (UPM) is considered a risk for cardiopulmonary vascular dysfunction. A 2017 study published in BMC Complementary and Alternative Medicine specifically investigated pulmonary protection: exposure to ambient urban particulate matter (UPM) is considered a risk for cardiopulmonary vascular dysfunction. To investigate the protective effect of CA against UPM-mediated collapse of the pulmonary alveolar epithelial (PAE) cell (NCI-H441), barrier integrity parameters and their elements were evaluated in PAE. To confirm the protection of PAE barrier integrity, paracellular permeability and the junctional molecules were estimated with determination of transepithelial electrical resistance, Western blotting, RT-PCR, and fluorescent staining.

Evidence strength: In vitro cell-based study (NCI-H441 human alveolar epithelial cells). Preliminary. No human clinical data exist for chebulic acid in respiratory conditions.

5.5 Neuroprotection (Ischemic Stroke Model)

A 2022 study published in Nutrients examined whether chebulic acid could protect against hypoxia insult via the Nrf2/ARE pathway in an ischemic stroke model. Excessive reactive oxygen species (ROS) production contributes to brain ischemia/reperfusion (I/R) injury through many mechanisms including inflammation, apoptosis, and cellular necrosis. Chebulic acid (CA) isolated from Terminalia chebula has been found to have various biological effects, such as antioxidants. In this study, investigators investigated the mechanism of the anti-hypoxic neuroprotective effect of CA in vitro and in vivo. The results showed that CA could protect against oxygen-glucose deprivation/reoxygenation (OGD/R) induced neurotoxicity in SH-SY5Y cells, as evidenced by the enhancement of cell viability and improvement of total superoxide dismutase (T-SOD) in SH-SY5Y cells. CA also attenuated OGD/R-induced elevations of malondialdehyde (MDA) and ROS in SH-SY5Y cells.

Chebulae Fructus provides neuroprotection by activating the Nrf2 signaling pathway, which in turn suppresses apoptosis.

Evidence strength: In vitro (neuroblastoma cell line SH-SY5Y) and early in vivo animal model evidence. No human clinical data.

5.6 Antimicrobial Activity

Literature survey reveals Terminalia chebula plant extracts possess good antibacterial activity against multidrug-resistant clinical strain of Acinetobacter baumannii. Four compounds — namely chebulinic acid, chebulagic acid, terchebulin, and corilagin — were identified on the basis of bioactive-guided fractions of the plant extract using high performance liquid chromatography (HPLC) to possess antimicrobial activity against A. baumannii.

T. chebula Retz. has been reported for its biological activities including anticancer, antidiabetic, antimutagenic, antibacterial, antifungal, and antiviral activities.

Among traditional Ayurvedic herbs, Terminalia chebula is widely used for the treatment of upper respiratory infections including cold and cough, and extensive research has shown that the fruit has antiviral property against influenza A virus. Studies have also demonstrated that treatment with the combination of Acyclovir (ACV), an anti-herpetic agent, and T. chebula was effective for treating HSV-1 infection in mouse models.

Evidence strength: In vitro and animal model studies. No clinical evidence exists specific to isolated chebulic acid in infectious disease.

5.7 Anti-Arthritic and Musculoskeletal Effects

Compounds such as corilagin, chebulanin, chebulagic acid, and chebulinic acid are cited for their efficacious impact in mitigating arthritis symptoms. Their anti-inflammatory activity is mainly achieved through the NF-κB and MAPK signaling pathways.

In 2020, Sujit Basu and collaborators at Ohio State University and KPC Medical College (Kolkata, India) described how chebulinic acid can help reduce the pain of rheumatoid arthritis (RA) patients. They noted that vascular endothelial growth factor-A (VEGF) induces angiogenesis in RA patients and that then-current anti-VEGF agents cause hypertension and other cardiovascular complications. They investigated reports that chebulinic acid can inhibit VEGF activity and found that it is a safe, potent antiangiogenic agent for treating RA.

Evidence strength: This evidence pertains largely to chebulinic acid (a related but distinct compound). Preclinical and in vitro. No dedicated human trials on isolated chebulic acid for arthritis.

5.8 Digestive and Gastrointestinal Effects

The parent plant, rather than the isolated compound, has most of the traditional gastro-intestinal applications. It is used in prescriptions for treating flatulence, constipation, diarrhea, dysentery, cyst, digestive disorders, and vomiting. Regarding isolated chebulinic acid (closely related compound): the gastro-protective mechanism of chebulinic acid isolated from Terminalia chebula fruit was investigated. Chebulinic acid was evaluated against cold restraint (CRU), aspirin (AS), alcohol (AL) and pyloric ligation (PL) induced gastric ulcer models in rats.

Evidence strength: Animal model data; no human clinical trials on isolated chebulic acid for gastrointestinal conditions.

6. Body Systems Associated with Chebulic Acid

Studies have identified approximately 149 compounds within the plant, including tannins, phenolic acids, lignans, triterpenes, flavonoids, and volatiles. These compounds confer a broad spectrum of biological activities in vitro and in vivo, such as antioxidant, anti-inflammatory, antiviral, anticancer, antibacterial, hepatoprotective, nephroprotective, neuroprotective, and anti-diabetic, some of which are already integrated into clinical practice.

Based on the preclinical scientific literature, the body systems most associated with chebulic acid's documented activity include:

Cardiovascular / Vascular system: AGE-induced endothelial dysfunction, monocyte adhesion, vascular ROS production.
Hepatic system: Nrf2-mediated cytoprotection, HO-1 induction, anti-fibrotic activity in stellate cells, protection from chemical hepatotoxins (CCl4, t-BHP, APAP).
Renal system: Reduction of proteinuria, albuminuria, and blood urea nitrogen in diabetic ischemia-reperfusion models.
Endocrine / Metabolic system: AGE inhibition relevant to diabetic complications, β-cell protection against methylglyoxal toxicity, serum glucose modulation in animal models.
Pulmonary system: Protection of alveolar epithelial barrier integrity against urban particulate matter.
Neurological system: Nrf2/ARE-mediated neuroprotection in hypoxia/ischemia models.
Gastrointestinal system: Traditional use (astringent, anti-dysenteric), with limited preclinical data on antiulcer activity of the related chebulinic acid.
Musculoskeletal / Immune system: Anti-inflammatory effects via NF-κB and MAPK suppression; antiangiogenic effects in RA models (primarily for related chebulinic acid).

7. Dosages Reported in Studies

The following doses are reported directly from published research sources; they are not recommendations and are presented only to characterize the experimental literature.

INS-1 pancreatic β-cells were pre-treated with CA (0.5, 1.0, and 2.0 µM) for 48 h and then treated with 2 mM MG for 8 h (in vitro cell-based study).
HUVEC were treated with chebulic acid at 25 µM in the presence of 100 µg/ml of glycer-AGEs (in vitro study).
The level of CA required for exerting antiglycating activity similar to aminoguanidine was 38.8 ± 0.5 µM (in vitro biochemical assay).
In vivo, chebulic acid at 25 and 50 mg/kg increases serum insulin levels and reduces blood urea nitrogen levels, proteinuria, albuminuria, and serum glucose levels in a diabetic rat model of ischemia-reperfusion-induced nephropathy (rodent study).
Oral administration of 10 mg of CA/kg b.w. for 2 weeks and 5 days at the same time injected with AGEs showed improved Nrf2 expression (animal study).
Studies have demonstrated that higher doses of CF (600 mg/kg) exhibit significant therapeutic potential, particularly showing enhanced anti-diabetic and antilipidemic effects, as well as pronounced hepatoprotective and renoprotective benefits (animal study; dose refers to whole extract, not isolated chebulic acid).
When 2000 mg/kg extract of T. chebula containing 29.4% chebulic acid was fed to rats for 14 days, no adverse effects were observed (animal safety study).

No standardized human clinical dosage for isolated chebulic acid has been established in available peer-reviewed literature as of the time this article was compiled. To date, no pharmacokinetic studies have investigated the peak blood concentration of CA in animals.

8. Safety Considerations

8.1 Preclinical Toxicology of the Parent Compound Class

Specific formal toxicology data on isolated chebulic acid in humans is absent from the available scientific literature. The available data are extrapolated from animal studies and from the closely related compound chebulinic acid. When 2000 mg/kg extract of T. chebula containing 29.4% chebulic acid was fed to rats for 14 days, no adverse effects were observed. This is an acutely high dose in a rodent model and does not directly translate to human safety parameters.

For chebulinic acid, a closely related compound from the same plant, a formal safety study was conducted. Acute oral toxicity test of chebulinic acid was conducted as per OECD guidelines 423. Photomicrographs of organs demonstrated normal architecture of lungs without observable signs of necrosis and apoptosis in bronchioles, kidney tissues showing no nephrotic vascular damage and necrotic lesions, pancreas representing no evidence of fibrosis and necrosis of islets of Langerhans, and spleen displaying normal histoarchitecture without apoptosis and necrosis from control and treated groups.

8.2 Lack of Human Clinical Safety Data for Isolated Compound

No completed human clinical trials specific to isolated chebulic acid have been identified in the scientific literature available at the time of writing. The safety profile is therefore extrapolated entirely from preclinical (in vitro and animal) studies and from the traditional use record of the whole fruit. To date, no pharmacokinetic studies have investigated the peak blood concentration of CA in animals. The absence of pharmacokinetic data is a significant limitation in assessing human safety.

8.3 Quality Control Considerations

The 2020 edition of the Chinese Pharmacopoeia lacks requirements for content determination, leading to gaps in quality control for T. chebula herbs. In this regard, a high-performance liquid chromatography (HPLC) method was established to determine chebulagic acid and chebulinic acid in T. chebula; it enhanced the content determination guidelines in the 2020 Chinese Pharmacopoeia and facilitated improved quality control of T. chebula herbs.

8.4 Potential for Tannin-Related Interactions

As a phenolic acid found in a tannin-rich plant, chebulic acid shares the general property of tannins to bind proteins, minerals, and some drugs in the gastrointestinal tract. High-tannin preparations from T. chebula may theoretically reduce absorption of co-administered medications or minerals; however, no published clinical interaction studies specific to chebulic acid as an isolated supplement ingredient have been identified in the reviewed peer-reviewed sources.

9. Current Research Gaps and Evidence Limitations

The research landscape for chebulic acid, as distinct from the whole fruit or the larger ellagitannins (chebulagic acid, chebulinic acid), remains in an early stage:

The majority of published studies are in vitro (cell-based), with a smaller number in rodent models. No completed randomized controlled human clinical trials isolating the specific effects of chebulic acid have been published in the peer-reviewed literature reviewed for this article.
To date, no pharmacokinetic studies have investigated the peak blood concentration of CA in animals, making it impossible to determine whether biologically active concentrations observed in vitro are achievable in vivo following oral administration.
Many published studies use the fruit extract or the related compounds chebulinic acid or chebulagic acid, and their results are not always directly attributable to isolated chebulic acid.
The compound exhibits activity against the Nrf2 pathway, AGE formation, and ROS generation across multiple organ systems, but the breadth of these preliminary findings has not yet been translated into clinical applications specific to this isolated molecule.
A 2022 review by Bhawna Chopra and colleagues at Guru Gobind Singh College of Pharmacy (Haryana, India) reviewed the pharmacological properties of chebulinic acid and related ellagitannins, examining biological properties including antitumor activity and antiatherogenic, antifibrotic, anti-inflammatory, antiulcer, antioxidant, hepatoprotective, antidiabetic, and antiviral effects — underscoring that the field has primarily reached the review-and-synthesis stage rather than human clinical translation.

References

Health Conditions

Health conditions that Chebulic acid may help support.

No conditions available.

Body Systems

Body systems that Chebulic acid may help support.

No body systems available.